BRIEF-Infotmic to withdraw delisting risk warning, share trade to halt on March 29
MOVES-Bank of America prime brokerage executive jumps to RBC
NEW YORK, June 14 Jonathan Yalmokas has resigned as Bank of America Corp's head of prime brokerage in the Americas to lead an equity financing business at Royal Bank of Canada, a person familiar with the move said on Wednesday.
Credit Suisse names AstraZeneca (NYSE:AZN) one of its potential surprise stocks for 2017, noting that high R&D success in a year of strong pipeline news flow - including the initial outcome of the MYSTIC lung cancer study - would drive the company faster to underlying growth.
Pipeline news expected in 2017, aside from MYSTIC, includes extending Lynparza to breast cancer, and extending Tagrisso to early-stage lung cancer. Outside oncology, there's roxadustat (anemia) and tralokinumab (severe asthma). We should also see the initial approval of durvalumab in bladder cancer.
Success in all projects currently weighted above 50% would mean AZN trades today at an 18% discount on EV/NPV.